Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M4nZR2Z2dmO2aX;uJGF{e2G7 MnvXNE42yqEQvF2= MlfDNlQhcA>? M4jzXJdifGW{ MlzrcY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM> NX7Jc3NGOjVzMkOwPFI>
Eca109 NVzjUVN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPMeVh[OC53L{KuOU82KM7:TR?= NH7nSHYzPC92OD:3NkBp MYr3ZZRmeg>? NYjSSIx2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> MoLuNlUyOjNyOEK=
Eca109 NWHIPXp7TnWwY4Tpc44hSXO|YYm= MnP0NE42yqEQvF2= NYjF[2J6Pi9zMj:yOEBp MXf3ZZRmeg>? MVvpcohq[mm2czDj[YxtKG2rZ4LheIlwdsLi MnS3NlUyOjNyOEK=
Eca109 NE\lV2RHfW6ldHnvckBCe3OjeR?= NWHqc|JSOC53wrFOwG0> M3rSN|I1KGh? MlPEe4F1\XJ? MkLJbY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? MYiyOVEzOzB6Mh?=
Eca109 NILmSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nM[|AvPcLizszN NUPIU3cxOjRiaB?= NXXyOnN3f2G2ZYK= MnX2bY5lfWOnczDHNk9OKGG{cnXzeEBqdiC2aHWgZ4VtdCCleXPs[S=> MljnNlUyOjNyOEK=
Eca109 MnzISpVv[3Srb36gRZN{[Xl? NVHYNGpbOC53L{Gg{txO MoLWNlQhcA>? M{PqbZdifGW{ MY\k[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz M1znU|I2OTJ|MEiy
SW1116  MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LyZlAvPS9zL{KvOUDPxE1? MWS0PEBp MUjEUXNQ MUXlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NGXrfZgzPDh5NEK4Oi=>
LOVO MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYOyT216OC53L{GvNk82KM7:TR?= MmnpOFghcA>? NHPpVmRFVVOR MlvF[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> MXWyOFg4PDJ6Nh?=
SW1116  MVnGeY5kfGmxbjDBd5NigQ>? MX[xNEDPxE1? Mo\pOFghcA>? MXPEUXNQ NYXJNoFwcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk M2frTFI1QDd2Mki2
LOVO MljTSpVv[3Srb36gRZN{[Xl? M1fI[VExKM7:TR?= MoDnOFghcA>? MVjEUXNQ NFz1TZdqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? M{f6OVI1QDd2Mki2
SW1116  NHLuZlRCeG:ydH;zbZMhSXO|YYm= MXOxNEDPxE1? MV60PEBp MXzEUXNQ M3fKRoVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> NUDWT2IyOjR6N{SyPFY>
LOVO NF\MRY5CeG:ydH;zbZMhSXO|YYm= MVuxNEDPxE1? M3TRR|Q5KGh? MUXEUXNQ NVLl[|dT\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ NHrnPJEzPDh5NEK4Oi=>
RPMI-8226 Ml7hRZBweHSxc3nzJGF{e2G7 NFv6R4wyNzJizszN MonUOFgwPzJxOU[gbC=> NX23WIdZTE2VTx?= NY\kSoF3cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MkjtNlQ5OzNzMEi=
OPM-2  M1fYbmFxd3C2b4Ppd{BCe3OjeR?= NETiW|AyNzJizszN MUm3Nk86Pi9zMkCgbC=> MWjEUXNQ M3PnWYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3PafFI1QDN|MUC4
JJN3  NU\Ye5dUSXCxcITvd4l{KEG|c3H5 NGm1VGsxNjVxMTFOwG0> MWOyOE81QCCq NW\5dVk{TE2VTx?= NIPk[GtqdmS3Y3XzJINmdGxiYYDvdJRwe2m| Mn7mNlQ5OzNzMEi=
NCI-H929  NYG3VIhRSXCxcITvd4l{KEG|c3H5 NHnrTncyNzJizszN MnvuO|IwQTZxMUKwJIg> NI\rWVFFVVOR NHXVc5FqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NXXPbY9KOjR6M{OxNFg>
RPMI-8226 NGqyeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\KT24yNzJizszN MV2yOE81QC95MjDo MWrEUXNQ NGLBU4di\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= Mn7lNlQ5OzNzMEi=
OPM-2  NFzXd5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrncIVROS9{IN88US=> MkDFNlQwPDhxN{KgbC=> M1\UW2ROW09? NHO0O3di\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NFLQWGMzPDh|M{GwPC=>
JJN3  MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnUOVQxNjVxMTFOwG0> MkPxNlQwPDhxN{KgbC=> MmO3SG1UVw>? NF7NXHZi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= M2DvRVI1QDN|MUC4
NCI-H929  NGj4OYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVyxM|Ih|ryP NF;ONIUzPC92OD:3NkBp M2jzcWROW09? NF6wW3Fi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MVeyOFg{OzFyOB?=
HeLa MUXLbY5ie2ViQYPzZZk> MmXMT4k:OTByMPMAl|UxODBizszNJIZweiCqRV7UNS=> MmKyNlQ4QDByOUi=
HeLa NFvGUYlMcW6jc3WgRZN{[Xl? M4DsO2tqRTVwNjFCtUAxNjVizszNJIZweiCqRV7UNi=> NWnj[|dROjR5OECwPVg>
HeLa Mk\xT4lv[XOnIFHzd4F6 NI\ZZnJMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy NWfD[oVjOjR5OECwPVg>
HeLa NVXFUHEzU2mwYYPlJGF{e2G7 MkLVT4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> NF:0c24zPDd6MEC5PC=>
NB4 M{LFdGZ2dmO2aX;uJGF{e2G7 MUSyMlUwPS95LkWvNVAh|ryP M3TO[|I1KGh? NVzVWG1DTE2VTx?= MWrpcoNz\WG|ZXGgeIhmKGW6cILld5Nqd25ib3[gdJJm[3W{c3;yJI1qWi1zMkXh NYn1VHFTOjR2OES4O|A>
CD4+ CD25− T  MWrGeY5kfGmxbjDBd5NigQ>? MXixM|Uh|ryP NGjxd|dz\WS3Y3XTJIdtd2KjbDDEUmEhdWW2aInsZZRqd25? NEDkWnYzPDR5NkO2NC=>
BV-173 MoP4RZBweHSxc3nzJGF{e2G7 MWWwMlI2NzBwNT:wMlc2NzFizszN NEDhbpk1QC95Mj:5OkBp NIrJWZnDqFCEUx?= MnS2bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NGm0PFQzPDR{M{[xNy=>
ML-1 NXj0[VlCSXCxcITvd4l{KEG|c3H5 MnLhNE4zPS9yLkWvNE44PS9zIN88US=> M1PYZlQ5Nzd{L{m2JIg> NIrsfJTDqFCEUx?= MUHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= M1LrTFI1PDJ|NkGz
HL-60 MVHBdI9xfG:|aYOgRZN{[Xl? M2jkZVAvOjVxMD61M|AvPzVxMTFOwG0> MlfBOFgwPzJxOU[gbC=> MYpCpHBDWw>? NWTDXXhjcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M3i5clI1PDJ|NkGz
KG-1a MY\BdI9xfG:|aYOgRZN{[Xl? M1jrVlAvOjVxMD61M|AvPzVxMTFOwG0> NF;iRWw1QC95Mj:5OkBp NET4V2jDqFCEUx?= MnOwbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M1HUfVI1PDJ|NkGz
BV-173 MXXGeY5kfGmxbjDBd5NigQ>? NH3D[JIzPTBxNUCwcm0> MXq0PEBp MWhCpHBDWw>? NYP2[VQzcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl NYmyeVlpOjR2MkO2NVM>
CEM MoDmSpVv[3Srb36gRZN{[Xl? MWOyOVAwPTBybl2= M3v5RVQ5KGh? MXdCpHBDWw>? NWjuO5JCcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MWOyOFQzOzZzMx?=
HL-60 NWnHfmNjTnWwY4Tpc44hSXO|YYm= MYeyOVAwPTBybl2= NHSwSJo1QCCq NWjvVnA5yqCSQmO= MU\pcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NIDWT5YzPDR{M{[xNy=>
ML-1 NET2SZVHfW6ldHnvckBCe3OjeR?= MWWyOVAwPTBybl2= MmTIOFghcA>? NGXH[3HDqFCEUx?= MUPpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? Ml;jNlQ1OjN4MUO=
DLD-1 MYjGeY5kfGmxbjDBd5NigQ>? NVvFV4RVOjVyL{WwNI5O NHrqcmc1QCCq NYHtRWVZyqCSQmO= NHTJVmRldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MWiyOFQzOzZzMx?=
HCT-116 M1z1UGZ2dmO2aX;uJGF{e2G7 NUCxVHFMOjVyL{WwNI5O M{noclQ5KGh? NFXOTWzDqFCEUx?= Mlnx[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? NYfO[pRzOjR2MkO2NVM>
U937-A/E-9/14/18  MUHBdI9xfG:|aYOgRZN{[Xl? MmrHNE4xOS9yLkGvNU8yOCEQvF2= NHGxUYE1QCCq NUfLV4dRcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXiyOFMxODR3Nh?=
HT29 MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\tboI4OiCq NV6zVWxrUUN3ME2xOFAxyrFzN{mg{txO M123bVI1OTd{ME[x
SW48 NVTINVl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfUV|Y{PzJiaB?= MlTkTWM2OD1zNT6yxtE3NjJizszN MnHGNlQyPzJyNkG=
HCT116 M1jDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH2O|IhcA>? MUDJR|UxRTFwN9MxNE41KM7:TR?= MYeyOFE4OjB4MR?=
HepG2 NXHJVFZYTnWwY4Tpc44hSXO|YYm= MkmwNE42NzFizszN NI\nXWozPCCq MXTEUXNQ M{jSU5VxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MmHhNlQyPDZ6N{S=
LS174T MYHGeY5kfGmxbjDBd5NigQ>? NH7kSnkxNjVxMTFOwG0> NWPidVlbOjRiaB?= MUXEUXNQ Mm\tcIVi\CC2bzDhckBqdmO{ZXHz[UBw\iCRQ2TONkBt\X[nbIO= NV\uXIlzOjRzNE[4O|Q>
HepG2 NGTzR|BCeG:ydH;zbZMhSXO|YYm= M3rhfVEwOTBxMUCwJO69VQ>? NIr0Olk4KGR? NWjnPJNJTE2VTx?= MkXlbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYK5TlJGOjRzNE[4O|Q>
LS174T NX3GTYxySXCxcITvd4l{KEG|c3H5 MnTwNU8yOC9zMECg{txO NV20TlUzPyCm M4TMR2ROW09? NYPlb3I2cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYfRPFBpOjRzNE[4O|Q>
QBC-939 NWrOS5o1SXCxcITvd4l{KEG|c3H5 MkfKNU8yOC9zMECg{txO M3nVUlch\A>? MmHISG1UVw>? MnTobY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVG2ZohvOjRzNE[4O|Q>
U251 MU\BdI9xfG:|aYOgRZN{[Xl? MWGxM|ExNzFyMDFOwG0> Mm\qO{Bl NHr3OpZFVVOR NVHmbpY2cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYOyOFE1Pjh5NB?=
HL-60 NX;Z[ZNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnENUDPxE1? NXf3XVRuPDhiaB?= M3;xd4lv[3KnYYPld{BIOi2yaHHz[UBk\WyuIH\yZYN1cW:w NFHZTJgzPDByMEOyOC=>
MDA‑MB‑453 NH7H[JNHfW6ldHnvckBCe3OjeR?= M2GzN|AvOi9zIN88US=> MXy3NkBp NX;ncZAy[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh NYX3WYdxOjN6NESyNlg>
HCC1569 MWfGeY5kfGmxbjDBd5NigQ>? MVewMlIwOSEQvF2= M1vFelczKGh? M3LuSINifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> NHXwR5ozOzh2NEKyPC=>
BT‑474 NHvBRmdHfW6ldHnvckBCe3OjeR?= MlnrNE4zNzFizszN M37LZlczKGh? NEDJcVFk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> Mn;kNlM5PDR{Mki=
AGS M2jSWmFxd3C2b4Ppd{BCe3OjeR?= NYn4Opl1PS9zMD:yNE82OCEQvF2= MXq0POKhcMLi MUjEUXNQ M3jOeIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0feKh M{XrdVI{PTh{N{i0
A549 NHvZdohCeG:ydH;zbZMhSXO|YYm= MlHuOU8yOC9{MD:1NEDPxE1? MXG0POKhcMLi MnzDSG1UVw>? NGn2UGpqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? MkTkNlM2QDJ5OES=
AGS  MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXRPFc2NzFyL{KwM|UxKM7:TR?= Mne3OFjDqGkEoB?= NVrTWIltTE2VTx?= MoOybY5lfWOnczDHNk9OKHCqYYPlJIFzemW|dNMg MlH6NlM2QDJ5OES=
Kasumi-1 NUT0ZWcxSXCxcITvd4l{KEG|c3H5 M1nCO|AvPSEQvF2= NYH1S5c3PDkEoHlCpC=> MlT1[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= M1Ls[FI{PDl|M{S4
OCI-AML3 MoH4RZBweHSxc3nzJGF{e2G7 M2HjVlIvPSEQvF2= MUm0POKhcMLi MXPk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= MlTqNlM1QTN|NEi=
MV4-11 MoTsRZBweHSxc3nzJGF{e2G7 MnnTNk42KM7:TR?= MXS0POKhcMLi NGn1elVl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> MVSyN|Q6OzN2OB?=
NK  M3Tvc2N6fG:2b4jpeJkhSXO|YYm= MofzNE4xOi1{MDFOwG0> NHPaSo82KGR? MoPq[IVkemWjc3XzJJRp\SCleYTvcJl1cWNiYXP0bZZqfHlib3[gUmsh[2WubIOgZZQhcW62ZYLt[YRq[XSnIHPvcoNmdnS{YYTpc45{KHKnc4XseIlv\yCrbjDhJHUue2ijcHXkJIRwe2YkgKPy[ZNxd26|ZTDjeZJ3\Q>? MXeyN|MzQDB6OB?=
NK  MmnFRZBweHSxc3nzJGF{e2G7 MYOwMlAzNTJyIN88US=> NUTqcIZDPSCm NVrCSlF6\GWlcnXhd4UhVktiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJkh[XNidHjlJINwdmOnboTyZZRqd25iaX7jdoVie2Wm M{\obVI{OzJ6MEi4
NK  NWfhZlVFTnWwY4Tpc44hSXO|YYm= NXfaTmltOC5yMT2yNEDPxE1? MVm1JIQ> NIjU[Ipk[XW|ZYOgbJlxd22ndHj5cIF1cW:wIH;mJG5MKGOnbHzzJIlvKGFiZH;z[gKBm3Knc4DvcpNm MWqyN|MzQDB6OB?=
MOLT4/DNR NHXJb4NHfW6ldHnvckBCe3OjeR?= NV71SlVMPSEQvF2= M4XKdFQh\A>? NYCxTWVMemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? MX2yN|A3ODV5MB?=
Jurkat/DOX NXPiTmo{TnWwY4Tpc44hSXO|YYm= Mon4OUDPxE1? M1XCZVQh\A>? NV\rZmdSemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? M3XmUVI{ODZyNUew
MOLT4/DNR M1XjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXrOUDPxE1? NX3SeGlyPCCm MkHXdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= MXKyN|A3ODV5MB?=
Jurkat/DOX MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPSOUDPxE1? Mln5OEBl NFrxUGlz\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 NInkdVAzOzB4MEW3NC=>
ccRCC  MmHXRZBweHSxc3nzJGF{e2G7 Mk\VNE4xOS1zMN88US=> MWi3NkBp M4XTcGROW09? MnSzbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? M2DTPFIzQDJ4NE[3
TNBC  NID2bJdCeG:ydH;zbZMhSXO|YYm= NF;5eW0xNjBzLUGw{txO M13sdlczKGh? NE\KNHlFVVOR NFGw[Ylp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w NYXWTmhuOjJ6Mk[0Olc>
A498 NXzsV|liSXCxcITvd4l{KEG|c3H5 MU[wMlAyNTFyzszN M2DwfVczKGh? MknRSG1UVw>? Mn:ybY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NWDCO3VWOjJ6Mk[0Olc>
KIJ265T MXXBdI9xfG:|aYOgRZN{[Xl? NFTJRo8xNjBzLUGw{txO NXfYbZNVPzJiaB?= M{fabGROW09? M1vL[Ilv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> MkD0NlI5OjZ2Nke=
MDA-231 Mn6wRZBweHSxc3nzJGF{e2G7 MXWwMlAyNTFyzszN M4\Yd|czKGh? M2LhOmROW09? NEfmUZFqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NUPobZJpOjJ6Mk[0Olc>
BT-20 NV7nPXZzSXCxcITvd4l{KEG|c3H5 MmCxNE4xOS1zMN88US=> NX3MU|dIPzJiaB?= MYPEUXNQ M2[1dIlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> M3PUeFIzQDJ4NE[3
U937 M{fiSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjLOU0zOCEQvF2= NXHHN41OOjRxNEivO|IhcA>? MUTpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MXKyNlc3PzB{MR?=
HL60 NHXOWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rGTVUuOjBizszN NYnSXnBXOjRxNEivO|IhcA>? MYPpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NXW3boFSOjJ5NkewNlE>
U937 NFTJR3RCeG:ydH;zbZMhSXO|YYm= Mn65NVUh|ryP MX6yOE81QC95MjDo MXXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXqyNlc3PzB{MR?=
HL60 M1rIcGFxd3C2b4Ppd{BCe3OjeR?= MknNNVUh|ryP MVSyOE81QC95MjDo NY\aOWF6cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NWHRWJBCOjJ5NkewNlE>
LS411N  M3f1TGFxd3C2b4Ppd{BCe3OjeR?= NYG0VFRnOC53IN88US=> M1PDc|czKGh? M4DIPYlv[3KnYYPld{BH[XNibWLORUBt\X[nbB?= NFHvTnEzOjR4MU[5OS=>
MDA-MB-231 NWnDW|ZGSXCxcITvd4l{KEG|c3H5 MkDyNVAh|ryP MUi0PEBp NHLzW4hz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MoPxNlE5QDd4OUe=
MCF-7  MoT6RZBweHSxc3nzJGF{e2G7 NYi5emlxOTBizszN NEXnUZo1QCCq NGjWeHNz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MV[yNVg5PzZ7Nx?=
A375 M1vtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofpNE42KM7:TR?= NFjMSo4yNzVxODDk M2XUR4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NIrwVYIzOTd7Nk[yNi=>
SKMEL1 M2\ZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnoSlAxNjVizszN MmnVNU82NzhiZB?= MV;pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NEezOpYzOTd7Nk[yNi=>
SKMEL3 Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGwMlUh|ryP NYfkVWY5OS93L{ig[C=> NITYV5dqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= M1nMWVIyPzl4NkKy
SKMEL28 NVrvcZBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVGwMlUh|ryP MmXQNU82NzhiZB?= MYfpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NIrsS3MzOTd7Nk[yNi=>
MeWo M{n4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S1cVAvPSEQvF2= MorsNU82NzhiZB?= MYTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NH;LdlMzOTd7Nk[yNi=>
B16 Ml3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj6eYZyOC53IN88US=> NGXt[FAyNzVxODDk M4Oz[4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NEniWFMzOTd7Nk[yNi=>
Ly 1 M1K5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[zZ|I1KGh? NUXDXJFiUUN3ME23MlMh|ryP NF;6NFYzOTd5MkC0PS=>
Ly 7 MkGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK5NlQhcA>? Mn7ETWM2OD1zMD63JO69VQ>? MnrnNlE4PzJyNEm=
Su-DHL6 NUe4RnhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvlNlQhcA>? M{W3fmlEPTExvK6yNEDPxE1? NH\PWpIzOTd5MkC0PS=>
Ly 10 MoP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX2e5gzPCCq MmTRTWM2OO,:nkKwJO69VQ>? NXzUcYdXOjF5N{KwOFk>
RIVA MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmyOEBp NW[2bY01UUN3MP-8olIxKM7:TR?= MnzxNlE4PzJyNEm=
Su-DHL2 Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTRWGRLOjRiaB?= MVnJR|Ux97zgMkCg{txO NXrxdlJKOjF5N{KwOFk>
Ly 1 NUXKeFV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO0PEBp M4PiT2lEPTB;MD6zOEDPxE1? NW\XVItNOjF5N{KwOFk>
Ly 7 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETMUnY1QCCq MnzKTWM2OD1yLkCyOUDPxE1? NVjOTXVvOjF5N{KwOFk>
Su-DHL6 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\mTXB2PDhiaB?= NF;FT4hKSzVy78{eNlAh|ryP MknUNlE4PzJyNEm=
Ly 10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHUOFghcA>? Mn\wTWM2OD1zLkig{txO M3m2eFIyPzd{MES5
RIVA MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L5R|Q5KGh? M{\DW2lEPTExvK6yNEDPxE1? MVKyNVc4OjB2OR?=
Su-DHL2 NFrTT3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXu0PEBp NI\KWZlKSzVyPUG3MlQh|ryP MoiyNlE4PzJyNEm=
Ly 1 NYC5RZpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO3NkBp MXrJR|UxRTBwMEGg{txO MUmyNVc4OjB2OR?=
Ly 7 MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTxT|FYPzJiaB?= NHfpe|ZKSzVyPUCuNFE5KM7:TR?= NFv5V24zOTd5MkC0PS=>
Su-DHL6 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXnUYs4OiCq MoHpTWM2OD1zLk[g{txO MWWyNVc4OjB2OR?=
Ly 10 M2exR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYW3NkBp NGO3bVJKSzVyPUGuNkDPxE1? M4HvU|IyPzd{MES5
RIVA NYjwenRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkThO|IhcA>? MULJR|Ux97zgMkCg{txO MU[yNVc4OjB2OR?=
Su-DHL2 M2\ZO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITlbGs4OiCq Ml\HTWM2OD1zMT6yJO69VQ>? NHztR4czOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID